Compare Roblox Corp (RBLX) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Roblox Corp vs Recursion Pharmaceuticals Inc — how do they compare? Roblox Corp trades at $49.6 (market cap $37.59B), while Recursion Pharmaceuticals Inc trades at $3 (market cap $1.63B). The key difference: Roblox Corp is far larger — about 23.1× Recursion Pharmaceuticals Inc's market cap. Which is the better fit depends on your goals.
| RBLX | RXRX | |
|---|---|---|
Market Cap | $37.59B | $1.63B |
Sector | Media | Health |
52-Week High | $141.56 | $6.79 |
52-Week Low | $41.30 | $2.84 |
Enterprise Value | $36.18B | $1.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Roblox trades at $52.50, up 1.59% with neutral technical signals. The company shows strong revenue growth reaching $4.89B in 2025 but continues to report significant losses with a -20.69% net margin. Analyst consensus is bullish with a $59.62 price target, though multiple class action lawsuits filed in July 2026 create near-term uncertainty. Operating cash flow improved to $1.8B, supporting ongoing platform investments.
Roblox presents a growth investment case with expanding user engagement and AI innovation, but profitability challenges and legal risks require careful monitoring. The stock offers 13.6% upside to consensus target, though high P/S ratio of 7.03 and negative ROE of -295.16% highlight valuation concerns amid persistent losses.
Recursion Pharmaceuticals (RXRX) trades at $2.89, down 1.87% with a bearish technical signal despite recent earnings beats. The company shows significant revenue growth challenges with 2025 revenue of $74.26M but massive losses of -$644.76M, resulting in a -851.51% net margin. Analyst sentiment is mixed with 40% buy ratings but a consensus price target of $7.83, representing 171% upside potential from current levels.
While RXRX offers substantial upside based on analyst targets, the stock carries high risk due to persistent losses, negative cash flow from operations, and unproven AI-driven drug discovery platform. The company's heavy reliance on financing activities to fund operations presents ongoing dilution risk, making this suitable only for risk-tolerant investors betting on long-term biotech breakthroughs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Roblox Corp
Roblox operates an online video game platform that lets young gamers create, develop, and monetize games (or experiences) for other players. The firm effectively offers its developers a hybrid of a game engine, publishing platform, online hosting and services, marketplace with payment processing, and social network. The platform is a closed garden that Roblox controls, earning revenue in multiple places while benefiting from outsourced game development. Unlike traditional video game publishers, Roblox is more focused on the creation of new tools and monetization techniques for its developers then creating new games or franchises. Roblox is increasingly focused on creating a metaverse that moves beyond games toward experiences like concerts, education, and even business management.
Read more on RBLX →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
